- Home
- SNES vs RDHL Comparison
SNES vs RDHL Comparison
Compare SNES & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | RDHL |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.3M |
| IPO Year | 2016 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SNES | RDHL |
|---|---|---|
| Price | $0.65 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 56.2K | ★ 869.5K |
| Earning Date | 11-09-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,000.00 | N/A |
| Revenue This Year | $30.39 | $17,592.31 |
| Revenue Next Year | $55.01 | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.56 | N/A |
| 52 Week Low | $0.63 | $0.44 |
| 52 Week High | $4.19 | $2.14 |
Technical Indicators
Market Signals| Indicator | SNES | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 45.63 |
| Support Level | $0.63 | N/A |
| Resistance Level | $0.87 | $1.07 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 22.36 | 34.96 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.